# 2026-11429: FDA Clears Protamine Sulfate for Generic Versions

2026-11429, Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-08, effective 2026-06-08; PRIA reads it as touching household money (as of 2026-06-15).

- Canonical: https://policyrisk.com/federal-register/2026-11429
- As of: 2026-06-15
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-11429
- Title: Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 34634
- Published: 2026-06-08
- Effective: 2026-06-08
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-15

## In one line

FDA Clears Protamine Sulfate for Generic Versions

## Summary

The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generics Can Keep Getting Approved: benefit, medium. If you make generic drugs, the FDA determined on June 8, 2026 that the listed products (including Protamine Sulfate 50 mg/5 mL) were not withdrawn for safety or effectiveness. That means FDA will not start proceedings to withdraw ANDA approvals that refer to these drugs and may continue to approve…
- Patients and Pharmacies Keep Access: benefit, medium. You (patients and pharmacies) can continue to rely on the listed medicines because FDA determined they were not withdrawn for safety or effectiveness and will keep related ANDAs listed and in place. The notice says approved ANDAs referring to these drugs are unaffected and additional ANDAs may be a…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-11429 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/08/2026-11429/determination-that-protamine-sulfate-protamine-sulfate-intravenous-solution-50-milligrams5)
- [2026-11429 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-08/pdf/2026-11429.pdf)

## Related
- [Previous: 2026-11428, Proposed Information Collection Activity; ACF-700 Tribal Annual Report](https://policyrisk.com/federal-register/2026-11428)
- [Next: 2026-11430, Agency Information Collection Activities; Proposed eCollection eComments Reques…](https://policyrisk.com/federal-register/2026-11430)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-11429 (as of 2026-06-15).
